INDEMNIFICATION AGREEMENTIndemnification Agreement • March 2nd, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledMarch 2nd, 2021 Company Industry JurisdictionTHIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [___________________] between Artiva Biotherapeutics, Inc., a Delaware corporation (the “Company”), and [___________] (“Indemnitee”).
Artiva Biotherapeutics, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • January 21st, 2022 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledJanuary 21st, 2022 Company Industry JurisdictionArtiva Biotherapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [●] additional shares (the “Optional Shares”) of Common Stock (“Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
INDEMNITY AGREEMENTIndemnity Agreement • April 8th, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledApril 8th, 2021 Company Industry JurisdictionTHIS INDEMNITY AGREEMENT (this “Agreement”) dated as of ___________ _____, 2021, is made by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (the “Company”), and [______] (“Indemnitee”).
OFFICE LEASEOffice Lease • April 8th, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledApril 8th, 2021 Company Industry JurisdictionThis Office Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between HSPF LA JOLLA COMMONS I INVESTORS LLC, a Delaware limited liability company (“Landlord”), and ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Tenant”).
Re: Employment Offer LetterArtiva Biotherapeutics, Inc. • April 8th, 2021 • Biological products, (no disgnostic substances)
Company FiledApril 8th, 2021 IndustryOn behalf of the Board of Directors of Artiva Biotherapeutics, Inc. (the “Company”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (this “Agreement”). These employment terms are contingent upon Board approval, and will be effective as of your start date, which will be on January 1, 2021 (the “Start Date”).
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • March 2nd, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledMarch 2nd, 2021 Company Industry JurisdictionTHIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of February 22, 2021, by and among Artiva Biotherapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.”
SELECTED PRODUCT LICENSE AGREEMENT (AB-101)Selected Product License Agreement • April 8th, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledApril 8th, 2021 Company IndustryTHIS SELECTED PRODUCT LICENSE AGREEMENT (the “Agreement”) is made and entered into as of November 21, 2019 (the “Effective Date”) by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having a place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121, USA, and GREEN CROSS LABCELL CORPORATION, a Korean corporation (“GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of South Korea. Artiva and GCLC are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
Private & ConfidentialArtiva Biotherapeutics, Inc. • April 8th, 2021 • Biological products, (no disgnostic substances)
Company FiledApril 8th, 2021 IndustryOn behalf of Artiva Biotherapeutics, Inc. (the “Company”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (this “Agreement”). These employment terms will be effective as of your start date, which will be on April 5, 2021 (the “Start Date”).
MASTER RESEARCH SERVICES AGREEMENT (For Selected Products)Master Research Services Agreement • April 8th, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledApril 8th, 2021 Company Industry JurisdictionTHIS MASTER RESEARCH SERVICES AGREEMENT (the “Agreement”) is made as of August 3, 2020 (the “Effective Date”), by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation, having an address of 4747 Executive Drive, Suite 1150, San Diego, CA 92121 (“Artiva”), and GREEN CROSS LABCELL CORPORATION, a Korean corporation, with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of Korea (“GCLC”).
Amendment No. 1 to Option and License AgreementOption and License Agreement • April 8th, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledApril 8th, 2021 Company IndustryThis Amendment No. 1 (this “Amendment”), effective as of June 23, 2020, amends certain provisions of the Option and License Agreement dated September 4, 2019, between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having its principal place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121 and GREEN CROSS LABCELL CORPORATION, a Korean corporation (“GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of South Korea (hereinafter the “Original Agreement”).
Amendment No. 1 to Master Agreement for Manufacturing ServicesMaster Agreement • April 8th, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledApril 8th, 2021 Company IndustryThis Amendment No. 1 (this “Amendment”), effective as of June 16, 2020, amends certain provisions of the Master Agreement for Manufacturing Services dated March 16, 2020, between Artiva Biotherapeutics, Inc. (“Company”), having its principal place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121 and Green Cross Cell Corporation, a Korean corporation (“Manufacturer”), with its principal place of business located at 107, lhyeon-ro 30 beon-gil, Giheung- gu, Yongin-si, Gyeonggi-do, 16924, Republic of South Korea (hereinafter the “Original Agreement”).
MERCK PARTNERED PRODUCT RESEARCH SERVICES AND LICENSE AGREEMENTServices and License Agreement • April 8th, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledApril 8th, 2021 Company Industry JurisdictionTHIS MERCK PARTNERED PRODUCT RESEARCH SERVICES AND LICENSE AGREEMENT (the “Agreement”) is made as of January 27, 2021 (the “Effective Date”), by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having an address of 4747 Executive Drive, Suite 1150, San Diego, CA 92121, and GREEN CROSS LABCELL CORPORATION, a Korean corporation (“GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of Korea.
EXCLUSIVE LICENSE AND RESEARCH COLLABORATION AGREEMENT by and between Artiva Biotherapeutics, Inc. and Merck Sharp & Dohme Corp.Exclusive License and Research Collaboration Agreement • April 8th, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledApril 8th, 2021 Company Industry JurisdictionThis Exclusive License and Research Collaboration Agreement (this “Agreement”) is effective as of January 27, 2021 (the “Effective Date”) and is entered into by and between Artiva Biotherapeutics, Inc., a corporation organized and existing under the laws of Delaware (“Company”) and Merck Sharp & Dohme Corp., a corporation organized and existing under the laws of New Jersey (“Merck”).
Private & ConfidentialArtiva Biotherapeutics, Inc. • June 6th, 2022 • Biological products, (no disgnostic substances)
Company FiledJune 6th, 2022 IndustryOn behalf of Artiva Biotherapeutics, Inc. (the “Company”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (this “Agreement”). These employment terms are contingent upon reference check and Board approval, and will be effective as of your start date, which will be on or before June 6, 2022 (the “Start Date”). This offer will become void if not accepted by May 24, 2022.
Agreement Confidential QA Controlled Document Master Agreement for Manufacturing Services March 16, 2020 / DCR001 AGR001.01Agreement Confidential Qa Controlled Document • April 8th, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledApril 8th, 2021 Company IndustryCERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
OPTION AND LICENSE AGREEMENTOption and License Agreement • April 8th, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledApril 8th, 2021 Company Industry JurisdictionTHIS OPTION AND LICENSE AGREEMENT (the “Agreement”) is made and entered into as of September 4, 2019 (the “Effective Date”) by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having a place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121, USA, and GREEN CROSS LABCELL CORPORATION, a Korean corporation (“GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of South Korea. Artiva and GCLC are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
Dated November 5, 2020 Affimed GmbH and Artiva Biotherapeutics, Inc. Strategic Collaboration AgreementStrategic Collaboration Agreement • April 8th, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledApril 8th, 2021 Company Industry JurisdictionThis Strategic Collaboration Agreement (Agreement) is made and entered into as of November 5, 2020 (the Effective Date) by and between Affimed GmbH, a German corporation having its principal office at Im Neuenheimer Feld 582, 69120 Heidelberg, Germany (Affimed) and Artiva Biotherapeutics, Inc. (Artiva), a US corporation having its principal office at, 4747 Executive Drive #1150, San Diego, CA 92121, USA (Artiva), (Affimed and Artiva each a Party and together the Parties).
SELECTED PRODUCT LICENSE AGREEMENT (AB-101)Product License Agreement • March 2nd, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMarch 2nd, 2021 Company IndustryTHIS SELECTED PRODUCT LICENSE AGREEMENT (the “Agreement”) is made and entered into as of November 21, 2019 (the “Effective Date”) by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having a place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121, USA, and GREEN CROSS LABCELL CORPORATION, a Korean corporation (“GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of South Korea. Artiva and GCLC are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
FIRST AMENDMENT TO LICENSE AGREEMENTLicense Agreement • June 6th, 2022 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledJune 6th, 2022 Company IndustryTHIS FIRST AMENDMENT TO LICENSE AGREEMENT (this “First Amendment”) is made as of May 9, 2022, by and between ARE-SD REGION NO. 37, LLC, a Delaware limited liability company (“Licensor”), and ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Licensee”).
Omnibus AmendmentArtiva Biotherapeutics, Inc. • March 7th, 2022 • Biological products, (no disgnostic substances)
Company FiledMarch 7th, 2022 IndustryThis Omnibus Amendment (this “Amendment”), effective as of February 3, 2022, is entered into by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having its principal place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121 and GC CELL CORPORATION (F/K/A GREEN CROSS LABCELL CORPORATION), a Korean corporation (“GC Cell” or “GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 16924, Republic of South Korea.
March 16th, 2019 Dr. Peter Flynn Re: Employment Offer Letter Dear PeterArtiva Biotherapeutics, Inc. • March 2nd, 2021 • Biological products, (no disgnostic substances)
Company FiledMarch 2nd, 2021 IndustryOn behalf of Artiva Biotherapeutics, Inc. (the “Company”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (this “Agreement”). These employment terms will be effective as of your start date, which will be April 15th, 2019 (the first date of your employment, the “Start Date”). This offer is contingent upon approval by the Company’s Board of Directors (the “Board”), and your successful completion of a background check to the satisfaction of the Company.
Re: Employment Offer LetterArtiva Biotherapeutics, Inc. • March 2nd, 2021 • Biological products, (no disgnostic substances)
Company FiledMarch 2nd, 2021 IndustryOn behalf of the Board of Directors of Artiva Biotherapeutics, Inc. (the “Company”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (this “Agreement”). These employment terms are contingent upon Board approval, and will be effective as of your start date, which will be on January 1, 2021 (the “Start Date”).
ARTIVA BIOTHERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for THOMAS J. FARRELLExecutive Employment Agreement • March 2nd, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledMarch 2nd, 2021 Company Industry JurisdictionThis Executive Employment Agreement (this “Agreement”), is made and entered into effective as of March 1, 2019 (the “Effective Date”), by and between Thomas J. Farrell (“Executive”) and Artiva Biotherapeutics, Inc., a Delaware corporation (the “Company”).
Re: Retention AgreementRetention Agreement • January 21st, 2022 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledJanuary 21st, 2022 Company IndustryThis letter sets forth the substance of the retention agreement (the “Agreement”) that Artiva Biotherapeutics, Inc. (the “Company”) is offering to you.
Amendment No. 1 to Strategic Collaboration AgreementStrategic Collaboration Agreement • December 16th, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledDecember 16th, 2021 Company IndustryThis Amendment No. 1 (the “Amendment”), effective as of October 18, 2021 (the “Amendment Date”), amends certain provisions of the Strategic Collaboration Agreement dated November 5, 2020 (the “Agreement”), between Affimed GmbH, a German corporation having its principal office at Im Neuenheimer Feld 582, 69120 Heidelberg, Germany (“Affimed”) and Artiva Biotherapeutics, Inc., a US corporation having its principal office at, 4747 Executive Drive #1150, San Diego, CA 92121, USA (“Artiva”), (Affimed and Artiva each a “Party” and together the “Parties”).
CONSULTING AGREEMENTConsulting Agreement • January 21st, 2022 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledJanuary 21st, 2022 Company Industry JurisdictionTHIS CONSULTING AGREEMENT (the “Agreement”) is made by and between ARTIVA BIOTHERAPEUTICS, INC. (“Company”) and FRED ASLAN, MD, an individual (“Consultant”), effective as of the date of last signature(the “Effective Date”).
October 15, 2021 VIA EMAIL Thomas J. Farrell Founder & Chief Strategy Officer Re: Separation Agreement Dear Tom:Employment Agreement • December 16th, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledDecember 16th, 2021 Company IndustryThis letter sets forth the substance of our agreement (the “Agreement”) regarding your transition and separation from Artiva Biotherapeutics, Inc. (the “Company”). This Agreement will become effective only upon the Effective Date specified in Section 9 below.